Insmed Moves to Dismiss SomatoKine Suit

Biopharmaceutical company Insmed has filed a motion to dismiss a lawsuit filed by Tercica and Genentech over efforts to commercialize its growth hormone SomatoKine in the U.S. The company said its activities concerning SomatoKine fall under federal clinical trial exemptions that prevent patent infringements from being filed against a product that is being tested in clinical trials.

Yahoo News (http://biz.yahoo.com/ap/050222/insmed_somatokine_1.html)